BioCentury
ARTICLE | Clinical News

X4 reports additional Phase I/II data for RCC candidate

May 18, 2018 7:11 PM UTC

X4 Pharmaceuticals Inc. (Cambridge, Mass.) reported data from 22 evaluable patients with advanced clear cell renal cell carcinoma (RCC) in a Phase I/II trial showing that X4P-001-IO plus Inlyta axitinib led to an objective response rate (ORR) of 31.8%, including one complete response and six partial responses, and a disease control rate (DCR) of 86.4%. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

The open-label, U.S. trial is enrolling about 83 advanced clear cell RCC patients who have failed at least one prior therapy. X4 previously reported data from the Phase I portion of the trial (see BioCentury, Nov. 30, 2017)...